GlobeNewsWire
24 Mar 2026, 21:49 UTC · 30w ago
Impact · against what's priced in
The failure of Valneva's Lyme disease vaccine candidate and subsequent legal scrutiny are severe negative catalysts. While the initial stock price drop reflects the trial failure, the new investigation into securities fraud introduces additional legal and financial liability.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
Valneva's Phase 3 VALOR clinical trial for its Lyme disease vaccine candidate failed to meet its primary endpoint.
More negative than 99% of claims this week
Valneva's ADR price dropped 37.11% following the announcement of the clinical trial results.
Continue reading
5 related stories
The Phase 3 VALOR trial failed to meet its primary endpoint, causing a 37.11% price drop, and the company now faces a securities fraud investigation by Pomerantz LLP.
Read from the article alone
No priced-in read yet
A class action lawsuit has been filed against Zoetis Inc., creating potential legal liabilities.
Read from the article alone
No priced-in read yet
A class action lawsuit has been filed against GRAIL, Inc., creating potential legal liabilities.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More negative than 90% of claims this week
Pomerantz LLP is investigating Valneva for potential securities fraud or unlawful business practices following the trial results.
More negative than 76% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is facing a potential class action lawsuit for securities fraud following a failed clinical trial endpoint and a 37% drop in stock price.
More negative than 85% of ticker scores this week
A class action lawsuit has been filed against the company.
More negative than 85% of ticker scores this week
A class action lawsuit has been filed against the company.
More negative than 63% of ticker scores this week
The company's Lyme disease vaccine candidate failed to meet its primary endpoint in a Phase 3 trial.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
2h ago
−13.4%
Price agrees with the score
$5.56 vs $6.42 close before publication (Mar 24) · not market-adjusted
VALN chart →−31.3%
Price agrees with the score
$79.62 vs $115.93 close before publication (Mar 24) · not market-adjusted
ZTS chart →+172.6%
Price is moving against the score
$132.60 vs $48.65 close before publication (Mar 24) · not market-adjusted
GRAL chart →
